| Autor: |
Robertson AG; School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia. lou.rendina@sydney.edu.au., Rendina LM |
| Jazyk: |
angličtina |
| Zdroj: |
Chemical Society reviews [Chem Soc Rev] 2021 Apr 07; Vol. 50 (7), pp. 4231-4244. Date of Electronic Publication: 2021 Feb 18. |
| DOI: |
10.1039/d0cs01075h |
| Abstrakt: |
According to the World Health Organization (WHO), there were 18.1 million new cancer cases and 9.6 million cancer deaths reported worldwide in 2018. These numbers are expected to rise over the next decade, and the development of new and effective cancer treatments and diagnostic tools is urgently required, particularly for aggressive and intractable malignant cancers such as those of the brain. An exciting field of cancer research involves combining therapeutic and diagnostic tools into a single 'theranostic' platform. The role of theranostics in the personalized management of oncology patients is increasing, as is the demand for new types of theranostic agents. Some of the most promising cancer theranostics exploit the lanthanoid metal gadolinium, an element possessing favourable therapeutic and imaging properties. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
